So it's being studied for good in that case, but it can also backfire in other ways that are not so good
Treatment outcomes appear similar between both approaches for appropriate patient populations
Emerging research suggests that GLP-1RAs may also be beneficial in treating conditions like obstructive sleep apnea (Malhotra et al., 2024), osteoarthritis (Bliddal et al., 2024), metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis with liver fibrosis (MASH) (Loomba et al., 2024), polycystic ovary syndrome (PCOS) (Szczesnowicz et al., 2023), Alzheimers disease (Liang et al., 2024), Parkinsons disease (Kalinderi et al., 2024), and addiction (Klausen et al., 2022)
A pilot open-label study by Sechi et al
A clean spray pattern in water is not proof that the final acidic or surfactant-rich formulation will remain stable after storage